Tomas J. Philipson
#183,174
Most Influential Person Now
Tomas J. Philipson's AcademicInfluence.com Rankings
Download Badge
Economics
Tomas J. Philipson's Degrees
- PhD Economics University of Pennsylvania
- Masters Economics University of Pennsylvania
- Bachelors Economics University of Chicago
Similar Degrees You Can Earn
Why Is Tomas J. Philipson Influential?
(Suggest an Edit or Addition)Tomas J. Philipson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The growth of obesity and technological change. (2009) (364)
- Disease Eradication: Private versus Public Vaccination (1997) (313)
- Rational Epidemics and Their Public Control (1996) (245)
- Welfare-Enhancing Technological Change and the Growth of Obesity. (2005) (239)
- The nonprofit sector and industry performance (2006) (190)
- Labor Supply and Weight (2007) (120)
- Nonprofit Production and Competition (1998) (100)
- Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation (2003) (99)
- How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. (2012) (98)
- The Rise in Old Age Longevity and the Market for Long-Term Care (1998) (96)
- Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates (2005) (92)
- Cost-effectiveness analysis and innovation. (2008) (85)
- Chapter 33 Economic epidemiology and infectious diseases (2000) (82)
- Integrated Insurance Design in the Presence of Multiple Medical Technologies (2007) (80)
- An Economic Evaluation of the War on Cancer (2009) (78)
- Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs (2005) (77)
- An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. (2012) (68)
- The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). (2015) (64)
- The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. (2012) (57)
- Geographic Variation in Health Care: The Role of Private Markets (2010) (56)
- Equilibrium and efficiency in an organized vote market (1996) (51)
- Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. (2010) (45)
- Cost-effectiveness as a price control. (2007) (43)
- Data Markets and the Production of Surveys (1997) (41)
- Endogenous cost-effectiveness analysis and health care technology adoption. (2013) (38)
- Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts (2008) (38)
- Technological Change and the Growth of Obesity (2002) (37)
- Clinical and economic outcomes of nutrition interventions across the continuum of care (2014) (37)
- Subject evaluation in social experiments (1998) (35)
- Aging and the Growth of Long-Term Care (1999) (32)
- Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. (2015) (32)
- `Me-Too' Innovation in Pharmaceutical Markets (2009) (32)
- The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data. (2011) (31)
- Government perspective: food labeling. (2005) (28)
- The empirical content of canonical models of infectious diseases: the proportional hazard specification (1995) (27)
- Experiments and subject sampling (1997) (27)
- Heterogeneity in action: the role of passive personalization in comparative effectiveness research. (2014) (26)
- Data Markets, Missing Data, and Incentive Pay (2001) (26)
- Surplus Appropriation from R&D and Health Care Technology Assessment Procedures (2006) (25)
- Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007. (2015) (25)
- Economic Burden of Disease-Associated Malnutrition in China (2015) (24)
- Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. (2010) (24)
- Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets (2012) (23)
- Drug licenses: a new model for pharmaceutical pricing. (2008) (23)
- Assessing the Safety and Efficacy of the Fda: The Case of the Prescription Drug User Fee Acts (2005) (23)
- Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (2004) (21)
- The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 (2010) (21)
- The Value of Diagnostic Testing in Personalized Medicine (2013) (20)
- The welfare loss of disease and the theory of taxation. (1995) (19)
- Intellectual Property and Marketing (2006) (19)
- Social Welfare and Measurement of Segregation (1993) (18)
- External Costs of Risky Health Behaviors Associated with Leading Actual Causes of Death in the U.S.: A Review of the Evidence and Implications for Future Research (2010) (18)
- The option value of innovative treatments in the context of chronic myeloid leukemia. (2012) (17)
- Infectious disease transmission and infection-dependent matching. (1998) (17)
- Economics of Obesity (2006) (17)
- Measurement errors: A principal investigator-agent approach (1999) (16)
- Can Medical Progress Be Sustained? Implications of the Link between Development and Output Markets (2011) (14)
- Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption (2009) (14)
- How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations (2016) (13)
- Association Between Breast Cancer Disease Progression and Workplace Productivity in the United States (2017) (13)
- The Option Value of Innovation (2012) (12)
- Tutorial on health economics and outcomes research in nutrition. (2014) (11)
- Dynamic cost-effectiveness of oncology drugs. (2012) (11)
- The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database (2008) (11)
- Innovation and Technology Adoption in Health Care Markets (2008) (10)
- Financial Health Economics (2014) (9)
- The wider public health value of HCV treatment accrued by liver transplant recipients. (2016) (9)
- Medical Care Output and Productivity in the Nonprofit Sector (2001) (8)
- Utilization effects of Rx-OTC switches and implications for future switches (2013) (8)
- Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? (2014) (8)
- The Regulation of Medical Innovation and Pharmaceutical Markets* (2002) (7)
- Medical Care Output and Productivity in the Nonprofit Sector (2001) (7)
- Multiple-output agency incentives in data production: experimental evidence (1997) (7)
- Five myths about cancer care in America. (2014) (7)
- Pricing and R&D When Consumption Affects Longevity (2002) (6)
- The evaluation of new health care technology: The labor economics of statistics (1997) (6)
- Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection (2016) (6)
- A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies (2014) (5)
- Public Liabilities and Health Care Policy (2012) (5)
- Technological Change and the Growth of Obesity: A Theoretical and Empirical Examination (2002) (5)
- Defining Value: The Need for a Longer, Broader View (2017) (4)
- A Reexamination of the Costs of Medical R&D Regulation (2012) (4)
- Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. (2015) (4)
- Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors (2013) (4)
- The exchange and allocation of decision power (1992) (4)
- Altruism and Innovation in Health Care (2010) (4)
- The Economic Value and Pricing of Personalized Medicine (2018) (3)
- Cost of Caution : the impact on Patients of Delayed Drug approvals (2010) (3)
- Specification analysis in mixed hazard models and a test of crossing survival functions (1999) (3)
- Health and Wealth Disparities in the United States (2010) (2)
- Supreme Court Amicus Brief Regarding Wyeth V. Diana Levine (2008) (2)
- Surplus Appropriation from R&D and Technology Assessment Procedures (2006) (2)
- PHP168 Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption (2011) (2)
- The new economics of human behavior: Public health and economic epidemiology (1995) (2)
- Labor Markets in Statistics: The Subject Supply Effect in Medical R&D (2016) (2)
- Valuing Health Technologies at NICE (2010) (2)
- The Institute of Medicine report on the FDA: where is the science? (2007) (2)
- Managed Care and the Quality of Health Care: A Misguided Debate? (2001) (1)
- Dynamic information release (1991) (1)
- Pricing and R&D with Related Margins (1998) (1)
- Striking a balance on new technology. Cost-effectiveness analysis can help sort out emerging health care technologies, but what are the consequences for continued medical innovation? (2006) (1)
- Data MArkets and OPtimal Sample Size Determination (1998) (1)
- Long-term ramifications of reimportation for the health care system. (2004) (1)
- Challenges in Studying Nutrition Interventions: Why Health Economic Research in Nutrition Is Needed (2016) (1)
- RAND Corporation From the SelectedWorks of Darius N . Lakdawalla September , 2006 Intellectual Property and Marketing (2017) (0)
- Smoking And Cancer Mortality: The Authors Reply. (2015) (0)
- 11. Economic Issues Associated with Incorporating Cost-Effectiveness Analysis into Public Coverage Decisions in the United States - Anupam B. Jena and Tomas J. Philipson (2015) (0)
- Managed Health Care and the Quality of Health Care: A Misguided Debate? (2002) (0)
- PIH24 Modeling the Health and Medical Care Spending of the Future Elderly: An Update Using the Future Elderly Model (2012) (0)
- Cost-Effectiveness As A Price (2007) (0)
- PCN92 THE WAR ON CANCER: AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL (2008) (0)
- The Economic Value of Medical Innovation (2012) (0)
- ISSUE BRIEF: THE IMPACT OF BIOPHARMACEUTICAL INNOVATION ON HEALTH CARE SPENDING (2022) (0)
- Response to Epstein's comment on "heterogeneity in action". (2014) (0)
- Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure. (2014) (0)
- Abstract 16196: The Economic Value of Statin Therapy (2011) (0)
- The Welfare Effects of FDA Regulation of Drugs (2012) (0)
- Editors' Summary (2010) (0)
- Financial Health Economics: Health, Productivity, and Risk Premia (2011) (0)
- 1 Is the Food And Drug Administration Safe And Effective ? (2007) (0)
- PHP18 OPTIMAL HEALTH POLICY AND THE LINK BETWEEN OUTPUT MARKETS AND DEVELOPMENT (2011) (0)
- Paying for cost-effective health care: Does it violate both static- and dynamic efficiency? (2015) (0)
- Cost Versus The Value Of Health Gains Quality-Adjusted Cost Of Care : A Meaningful Way To Measure Growth In Innovation and (2015) (0)
- PCV67 Pharmacy Cost Sharing, Antiplatelet Therapy Utilization, and Health Outcomes for Patients with Acute Coroncary Syndrome (2012) (0)
- The importance of model inputs and assumptions in conducting health technology assessments of novel drugs (2017) (0)
- Abstract P1-11-07: The relationship between breast cancer progression and workplace productivity in the US (2016) (0)
- CEA: The Authors Respond (2007) (0)
- Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases (2013) (0)
- WORKING PAPER SERIES INTELLECTUAL PROPERTY AND MARKETING (2006) (0)
- PMH79 The Impact of Comparative Effectiveness Research on Health and Health Care Spending (2011) (0)
- The Benefits of Greater Data Exclusivity under the Hatch-Waxman Act (2009) (0)
- The Regulation of Medical Products (2012) (0)
- RAND Corporation From the SelectedWorks of Darius N . Lakdawalla September , 2006 The Nonprofit Sector and Industry Performance (2017) (0)
- The Value of Medical Innovation Versus Industry Rewards. (2022) (0)
- Breast cancer progression and workplace productivity. (2015) (0)
- Market Exclusivity For Drugs: The Authors Reply (2011) (0)
- Value of Cancer Spending (2012) (0)
- Quantifying the Value of Personalized Medicines (2013) (0)
- NON-ADHERENCE AND PERSONALIZED MEDICINE: A POSITIVE AND NORMATIVE ANALYSIS (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Tomas J. Philipson?
Tomas J. Philipson is affiliated with the following schools:
